KX-826 users: 0.5% vs 0.9% vs foam Technology 8/3/2025
KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.
View this post in the Community →
Similar Community Posts Join
5 / 445 resultscommunity If we lose hair because of our sensitivity to DHT, then why are we trying to reduce DHT when our sensitive androgen receptors are the culprit?
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
community Why are there no meaningful baseline blood tests for pyrilutamide (KX-826) like there are for finasteride?
Finasteride reduces DHT production, so blood tests can track hormonal changes. Pyrilutamide blocks androgen receptors without altering hormone levels, making blood tests less useful for detecting its effects.
community New angles to attack beyond DHT
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
community Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community How much faith do you have in Kintor?
KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.
Related Research
6 / 225 results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
New treatments for hair loss show promise but need more testing for effectiveness and safety.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research Mechanism exploration of the combined use of minoxidil with natural compounds ginsenoside Rg3 and glycyrrhizic acid for enhancing androgenic alopecia therapy
Combining minoxidil with ginsenoside Rg3 and glycyrrhizic acid offers a more effective treatment for androgenic alopecia.
research Molecular Mechanisms and Targeted Therapeutics in Androgenetic Alopecia: From Signaling Pathways to Regenerative Approaches
Future treatments for hair loss may focus on personalized and regenerative approaches.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.